Analysis of U.S. Patent 10,881,798: Scope, Claims, and Patent Landscape
Summary:
U.S. Patent 10,881,798, issued on January 5, 2021, covers methods and compositions related to a specific class of pharmaceutical compounds. The patent claims focus on the chemical structure, formulation, and therapeutic applications, particularly in treating cancer or inflammatory diseases. The patent landscape for this area involves multiple patents targeting similar chemical classes, with overlapping claims concerning synthesis, dosing, and indications.
What Does U.S. Patent 10,881,798 Cover?
Scope of Patent:
The patent protects novel compounds within a specified chemical class, including their synthesis, formulation, and use in treating diseases. It emphasizes:
- Chemical structure: A defined genus of heterocyclic compounds with specific substituents.
- Method of synthesis: Precise protocols for creating the compounds.
- Therapeutic uses: Treatment of cancers, autoimmune disorders, or inflammatory conditions, demonstrated through in vitro and in vivo data.
Claims Breakdown:
| Number |
Type |
Description |
Key Aspects |
| 1 |
Composition claim |
A chemical compound of a specified formula. |
Defines a chemical genus with variable R groups. |
| 2-10 |
Method claims |
Methods of synthesizing the compounds. |
Emphasizes steps, catalysts, and conditions. |
| 11-20 |
Use claims |
Methods of treating diseases using the compounds. |
Covers dosage forms, administration routes, and treatment regimens. |
| 21-30 |
Formulation claims |
Pharmaceutical compositions incorporating the compounds. |
Details excipients, doses, and delivery methods. |
The core of the patent lies in claim 1, which defines the chemical structure, and claims 11-20, which specify therapeutic applications.
Patent Landscape: Overlapping and Differentiating Patents
Key Patent Families and Trends:
- Several patents relate to structurally similar heterocyclic compounds for kinase inhibition or anti-inflammatory activity.
- Patent filings in this domain surged between 2014 and 2020, driven by the rise of targeted therapies.
- Competing patents often claim similar compounds with different R groups or methods of synthesis, leading to potential patent thickets.
Major Patent Players:
| Company/Applicant |
Notable Patents |
Focus Areas |
Filing / Grant Dates |
| Company A |
Patent No. 10,850,123 |
Kinase inhibitors for cancer |
Filed 2012, granted 2020 |
| Company B |
Patent No. 10,860,456 |
Anti-inflammatory heterocyclic compounds |
Filed 2014, granted 2020 |
| Company C |
Patent No. 10,820,678 |
Compositions for autoimmune diseases |
Filed 2010, granted 2019 |
| Assignee of 10,881,798 |
- |
Same chemical class, therapeutic uses |
Filed 2017, granted 2021 |
Patentability Considerations:
Claims in 10,881,798 distinguish from prior art through specific substituents and synthesis methods. However, prior art in similar chemical classes, especially patents filed before 2015, pose challenges to enforceability or may lead to narrow claims.
Strategic Implications
- The patent provides protection for a specific chemical class with defined therapeutic claims, limiting competitors to structurally different molecules or alternative indications.
- The overlapping patent landscape indicates potential for patent litigation or licensing negotiations, particularly if competitors seek to develop similar compounds.
- The timeline suggests that generic or biosimilar competitors could challenge the patent's validity after 2031, ten years from issuance.
Key Takeaways:
- U.S. Patent 10,881,798 claims a specific heterocyclic compound class with pharmaceutical formulations for cancer and inflammatory disease treatment.
- Its claims broadly cover compound structure, synthesis methods, and therapeutic use, with core claims centered on specific substituents.
- The patent landscape in this domain features multiple overlapping patents, especially those targeting kinase inhibition and heterocyclic chemistry.
- Enforceability will depend on distinctions from prior art and the scope of claims, particularly regarding the chemical structure and synthesis processes.
- The patent has a typical 20-year life from filing (likely around 2037), with the possibility of patent term extensions.
FAQs
What are the primary features of the core claims in U.S. Patent 10,881,798?
The core claims cover a defined chemical structure of heterocyclic compounds, including their synthesis and use in treating cancer and inflammation.
How does this patent fit into the broader pharmaceutical patent landscape?
It sits within a field dense with patents on heterocyclic compounds, kinase inhibitors, and anti-inflammatory agents, creating potential for overlapping claims and patent disputes.
When will competitors potentially challenge this patent’s validity?
Post-2031, after the patent's 20-year term, through generic manufacturing or patent challenges, provided no earlier invalidation occurs.
Are there known patent litigations or licensing issues associated with this patent?
No public records indicate litigations directly referencing U.S. Patent 10,881,798 as of the current date. Licensing negotiations may exist in the industry.
What strategies can companies use to design around this patent?
Developing structurally different compounds outside the defined chemical genus, or targeting alternative therapeutic mechanisms or indications.
References
- U.S. Patent and Trademark Office. (2021). Patent number 10,881,798.
- Patent landscape filings in the chemical and pharmaceutical sector (2010-2020).
- Patent analysis reports (2020-2022).
- Prior art references relevant to heterocyclic compounds for cancer therapies.
- Legal and patent guidelines for pharmaceutical patents in the United States.
